Clinical Trial Update: Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating milademetan plus quizartinib in FLT3-ITD mutant acute myeloid leukemia has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Milademetan (milademetan)
• Quizartinib (Quizartinib)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Acute Myeloid Leukemia | Phase 1 | Status: TERMINATED | Results posted: 2022-05-20